Inhibition of 11β-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?

References

• Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593–5602 (2003).
   PubMed Web of Science ®Google Scholar
• Nosadini R, Del Prato S, Tiengo A et al. Insulin resistance in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 57(3), 529–536 (1983).
   PubMed Web of Science ®Google Scholar
• Faggiano A, Pivonello R, Spiezia S et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 88(6), 2527–2533 (2003).
   PubMed Web of Science ®Google Scholar
• •Study demonstrates potential for great impact on cardiovascular disease by lowering glucocorticoid levels.
   Google Scholar
• Magiakou MA, Mastorakos G, Zachman K, Chrousos GP. Blood pressure in children and adolescents with Cushing’s syndrome before and after surgical care. J. Clin. Endocrinol. Metab. 82(6), 1734–1738 (1997).
   PubMed Web of Science ®Google Scholar
• Fallo F, Sonino N, Barzon L et al. Effect of surgical treatment on hypertension in Cushing’s syndrome. Am. J. Hypertens. 9(1), 77–80 (1996).
   PubMedGoogle Scholar
• Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 13(9), 795–803 (1997).
   PubMed Web of Science ®Google Scholar
• Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect ‘Cushing’s disease of the omentum’? Lancet 349(9060), 1210–1213 (1997).
   PubMed Web of Science ®Google Scholar
• •Authors articulate hypothesis that elevated intracellular glucocorticoid tone in visceral adipose may underlie metabolic syndrome.
   Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12), 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. The PROspective CArdiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J. 116(6 Pt. 2), 1713–1724 (1988).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Valdez RA, Hazuda HP et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41(6), 715–722 (1992).
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Lakka HM, Niskanen LK et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156(11), 1070–1077 (2002).
   Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21), 2709–2716 (2002).
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of Type 2 diabetes: the San Antonio heart study. Diabetes Care 26(11), 3153–3159 (2003).
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24(4), 683–689 (2001).
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26(4), 1251–1257 (2003).
   PubMed Web of Science ®Google Scholar
• Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110(4), 380–385 (2004).
   PubMed Web of Science ®Google Scholar
• Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110(10), 1245–1250 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National cholesterol education program versus world health organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio heart study. Circulation 110(10), 1251–1257 (2004).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 287(3), 356–359. (2002).
   PubMed Web of Science ®Google Scholar
• McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28(2), 385–390 (2005).
   PubMed Web of Science ®Google Scholar
• Golden SH, Folsom AR, Coresh J et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51(10), 3069–3076 (2002).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 15(7), 539–553 (1998).
   PubMed Web of Science ®Google Scholar
• World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, World Health Org. (WHO/NCD/NCS99.2). Geneva, Switzerland (1999).
   Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Munck A, Naray-Fejes-Toth A. The ups and downs of glucocorticoid physiology. Permissive and suppressive effects revisited. Mol. Cell. Endocrinol. 90(1), C1–C4. (1992).
   PubMedGoogle Scholar
• den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 24(4), 644–649 (2004).
   PubMed Web of Science ®Google Scholar
• Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87(7), 3023–3028 (2002).
   PubMed Web of Science ®Google Scholar
• Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279(31), 32345–32353 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin CS, Hirsch A, Fung C, Rosen OM. Development of hormone receptors and hormonal responsiveness in vitro. Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells. J. Biol. Chem. 253(20), 7570–7578 (1978).
   PubMed Web of Science ®Google Scholar
• Hauner H, Schmid P, Pfeiffer EF. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J. Clin. Endocrinol. Metab. 64(4), 832–835 (1987).
   PubMed Web of Science ®Google Scholar
• Livingston JN, Lockwood DH. Effect of glucocorticoids on the glucose transport system of isolated fat cells. J. Biol. Chem. 250(21), 8353–8360 (1975).
   PubMedGoogle Scholar
• Olefsky JM. Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J. Clin. Invest. 56(6), 1499–1508 (1975).
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Jones DS. Glucocorticoid-induced insulin resistance in vitro: inhibition of insulin-stimulated methylaminoisobutyric acid uptake. Horm. Metab. Res. 18(3), 149–152 (1986).
   PubMedGoogle Scholar
• Ekstrand A, Saloranta C, Ahonen J, Gronhagen-Riska C, Groop LC. Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man. Metabolism 41(7), 692–697 (1992).
   PubMedGoogle Scholar
• Davani B, Khan A, Hult M et al. Type 1 11β-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J. Biol. Chem. 275(45), 34841–34844 (2000).
   PubMed Web of Science ®Google Scholar
• Hollingdal M, Juhl CB, Dall R et al. Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 45(1), 49–55 (2002).
   PubMedGoogle Scholar
• Nobel S, Abrahmsen L, Oppermann U. Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur. J. Biochem. 268(15), 4113–4125 (2001).
   PubMedGoogle Scholar
• Hosfield DJ, Wu Y, Skene RJ et al. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase Type I provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 280(6), 4639–4648 (2005).
   PubMed Web of Science ®Google Scholar
• Ogg D, Elleby B, Norstrom C et al. The crystal structure of guinea-pig 11β-hydroxysteroid dehydrogenase Type 1 provides a model for enzyme-lipid bilayer interactions. J. Biol. Chem. 280(5), 3789–3794 (2005).
   PubMedGoogle Scholar
• Zhang J, Osslund TD, Plant MH et al. Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1: An important therapeutic target for diabetes. Biochemistry 44(18), 6948–6957 (2005).
   PubMedGoogle Scholar
• Tomlinson JW, Walker EA, Bujalska IJ et al. 11{β}-Hydroxysteroid Dehydrogenase Type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. (2004).
   PubMedGoogle Scholar
• Lakshmi V, Monder C. Purification and characterization of the corticosteroid 1β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 123(5), 2390–2398 (1988).
   PubMed Web of Science ®Google Scholar
• Walker EA, Clark AM, Hewison M, Ride JP, Stewart PM. Functional expression, characterization, and purification of the catalytic domain of human 11-β -hydroxysteroid dehydrogenase Type 1. J. Biol. Chem. 276(24), 21343–21350 (2001).
   PubMedGoogle Scholar
• Agarwal AK, Tusie-Luna MT, Monder C, White PC. Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol. Endocrinol. 4(12), 1827–1832 (1990).
   PubMed Web of Science ®Google Scholar
• Murphy BE. Specificity of human 11β-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 14(8), 807–809 (1981).
   Google Scholar
• Frey FJ. Kinetics and dynamics of prednisolone. Endocr. Rev. 8(4), 453–473 (1987).
   PubMedGoogle Scholar
• Maser E, Bannenberg G. 11β-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem. Pharmacol. 47(10), 1805–1812 (1994).
   PubMed Web of Science ®Google Scholar
• Maser E. 11β-hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes. Cancer Res. 58(14), 2996–3003 (1998).
   PubMed Web of Science ®Google Scholar
• Finckh C, Atalla A, Nagel G, Stinner B, Maser E. Expression and NNK reducing activities of carbonyl reductase and 11β-hydroxysteroid dehydrogenase Type 1 in human lung. Chem. Biol. Interact. 130–132(1–3), 761–773 (2001).
   PubMed Web of Science ®Google Scholar
• Mziaut H, Korza G, Hand AR, Gerard C, Ozols J. Targeting proteins to the lumen of endoplasmic reticulum using N-terminal domains of 11β-hydroxysteroid dehydrogenase and the 50-kDa esterase. J. Biol. Chem. 274(20), 14122–14129 (1999).
   PubMedGoogle Scholar
• Atanasov AG, Nashev LG, Schweizer RA, Frick C, Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11β-hydroxysteroid dehydrogenase Type 1 as an oxoreductase. FEBS Lett. 571(1–3), 129–133 (2004).
   PubMed Web of Science ®Google Scholar
• Bujalska IJ, Draper N, Michailidou Z et al. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11β-hydroxysteroid dehydrogenase Type 1. J. Mol. Endocrinol. 34(3), 675–684 (2005).
   Google Scholar
• Kotelevtsev Y, Brown RW, Fleming S et al. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase Type 2. J. Clin. Invest. 103(5), 683–689 (1999).
   PubMed Web of Science ®Google Scholar
• Spencer RL, Kim PJ, Kalman BA, Cole MA. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic–pituitary–adrenal axis activity. Endocrinology 139(6), 2718–2726 (1998).
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294(5549), 2166–2170 (2001).
   PubMed Web of Science ®Google Scholar
• ••Mice overexpressing hydroxysteroid dehydrogenase (11β-HSD)1 in the adipose develop features of metabolic syndrome.
   Google Scholar
• Masuzaki H, Yamamoto H, Kenyon CJ et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112(1), 83–90 (2003).
   PubMed Web of Science ®Google Scholar
• Rask E, Olsson T, Soderberg S et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 86(3), 1418–1421 (2001).
   PubMed Web of Science ®Google Scholar
• •Obese humans exhibit elevated 11β-HSD1 activity in abdominal subcutaneous adipose tissue.
   Google Scholar
• Afdhal NH, Masuzaki H, Turner B, Nasser I, Flier J. Transgenic mice with 11b-hydroxysteroid dehydrogenase Type 1 overexpression in adipocytes develop fatty liver disease. Hepatology 36(4 Part 2), 216A (2002).
   Google Scholar
• Rooman R, Koster G, Bloemen R, Gresnigt R, van Buul-Offers SC. The effect of dexamethasone on body and organ growth of normal and IGF-II-transgenic mice. J. Endocrinol. 163(3), 543–552 (1999).
   PubMedGoogle Scholar
• Paterson JM, Morton NM, Fievet C et al. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase Type 1 in transgenic mice. Proc. Natl Acad. Sci. USA 101(18), 7088–7093 (2004).
   PubMed Web of Science ®Google Scholar
• Kotelevtsev Y, Holmes MC, Burchell A et al. 11β-hydroxysteroid dehydrogenase Type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA (PNAS) 94(26), 14924–14929 (1997).
   PubMedGoogle Scholar
• ••Deficiency of 11β-HSD1 in mice leads to protection from features of metabolic syndrome.
   Google Scholar
• Morton NM, Holmes MC, Fievet C et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase Type 1 null mice. J. Biol. Chem. 276(44), 41293–41300 (2001).
   PubMed Web of Science ®Google Scholar
• Morton NM, Paterson JM, Masuzaki H et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase Type 1-deficient mice. Diabetes 53(4), 931–938 (2004).
   PubMed Web of Science ®Google Scholar
• Justesen J, Mosekilde L, Holmes M et al. Mice deficient in 11β-hydroxysteroid dehydrogenase Type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 145(4), 1916–1925 (2004).
   PubMed Web of Science ®Google Scholar
• Hundertmark S, Dill A, Ebert A et al. Foetal lung maturation in 11β-hydroxysteroid dehydrogenase Type 1 knockout mice. Horm. Metab. Res. 34(10), 545–549. (2002).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Morton NM, Dhillon H et al. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54(4), 1023–1031 (2005).
   PubMed Web of Science ®Google Scholar
• •Overexpression of 11β-HSD2 in adipose protects from features of metabolic syndrome and recapitulates the phenotype of the 11β-HSD1 knockout mice.
   Google Scholar
• Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 142(1), 114–120 (2001).
   PubMed Web of Science ®Google Scholar
• White PC, Mune T, Agarwal AK. 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 18(1), 135–156 (1997).
   PubMed Web of Science ®Google Scholar
• Phillipou G, Higgins BA. A new defect in the peripheral conversion of cortisone to cortisol. J. Steroid Biochem. Mol. Biol. 22(3), 435–436 (1985).
   Google Scholar
• Biason-Lauber A, Suter SL, Shackleton CH, Zachmann M. Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism. Horm. Res. 53(5), 260–266 (2000).
   PubMedGoogle Scholar
• Tomlinson JW, Draper N, Mackie J et al. Absence of Cushingoid phenotype in a patient with Cushing’s disease due to defective cortisone to cortisol conversion. J. Clin. Endocrinol. Metab. 87(1), 57–62 (2002).
   PubMedGoogle Scholar
• Taylor NF, Bartlett WA, Dawson DJ, Enoch BA. Cortisone reductase deficiency: evidence for a new inborn error in metabolism of adrenal steroids. J. Endocrinol. 102S, 90 (1984).
   PubMedGoogle Scholar
• Nordenstrom A, Marcus C, Axelson M, Wedell A, Ritzen EM. Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11β-hydroxysteroid dehydrogenase reductase activity. J. Clin. Endocrinol. Metab. 84(4), 1210–1213 (1999).
   PubMed Web of Science ®Google Scholar
• Phillipov G, Palermo M, Shackleton CH. Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J. Clin. Endocrinol. Metab. 81(11), 3855–3860 (1996).
   PubMedGoogle Scholar
• Jamieson A, Wallace AM, Andrew R et al. Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase Type 1. J. Clin. Endocrinol. Metab. 84(10), 3570–3574 (1999).
   PubMedGoogle Scholar
• Malunowicz EM, Romer TE, Urban M, Bossowski A. 11β-hydroxysteroid dehydrogenase Type 1 deficiency (‘apparent cortisone reductase deficiency’) in a 6-year-old boy. Horm. Res. 59(4), 205–210 (2003).
   PubMedGoogle Scholar
• Draper N, Echwald SM, Lavery GG et al. Association studies between microsatellite markers within the gene encoding human 11β-hydroxysteroid dehydrogenase Type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J. Clin. Endocrinol. Metab. 87(11), 4984–4990 (2002).
   PubMed Web of Science ®Google Scholar
• Gelernter-Yaniv L, Feng N, Sebring NG, Hochberg Z, Yanovski JA. Associations between a polymorphism in the 11β hydroxysteroid dehydrogenase Type I gene and body composition. Int. J. Obes. Relat. Metab. Disord. 27(8), 983–986 (2003).
   PubMed Web of Science ®Google Scholar
• Nair S, Lee YH, Lindsay RS et al. 11β-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 47(6), 1088–1095 (2004).
   PubMed Web of Science ®Google Scholar
• Robitaille J, Brouillette C, Houde A et al. Molecular screening of the 11β-HSD1 gene in men characterized by the metabolic syndrome. Obes. Res. 12(10), 1570–1575 (2004).
   PubMedGoogle Scholar
• Draper N, Walker EA, Bujalska IJ et al. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase Type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genet. 34(4), 434–439 (2003).
   PubMed Web of Science ®Google Scholar
• Hewitt KN, Walker EA, Stewart PM. Minireview: hexose-6-phosphate dehydrogenase and redox control of 11β-hydroxysteroid dehydrogenase Type 1 activity. Endocrinology 146(6), 2539–2543 (2005).
   PubMed Web of Science ®Google Scholar
• San Millan JL, Botella-Carretero JI, Alvarez-Blasco F et al. A Study of the hexose-6-phosphate dehydrogenase gene R453Q and 11β-hydroxysteroid dehydrogenase Type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90(7), 4157–4162 (2005).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Stewart PM. The functional consequences of 11β-hydroxysteroid dehydrogenase expression in adipose tissue. Horm. Metab. Res. 34(11–12), 746–751 (2002).
   PubMedGoogle Scholar
• Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase Type 1 in adipose tissue is not increased in human obesity. J. Clin. Endocrinol. Metab. 87(12), 5630–5635 (2002).
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Feldpausch M et al. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 12(1), 9–17 (2004).
   PubMedGoogle Scholar
• Rask E, Walker BR, Soderberg S et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase Type 1 activity. J. Clin. Endocrinol. Metab. 87(7), 3330–3336 (2002).
   PubMed Web of Science ®Google Scholar
• Wake DJ, Rask E, Livingstone DE et al. Local and systemic impact of transcriptional upregulation of 11β-hydroxysteroid dehydrogenase Type 1 in adipose tissue in human obesity. J. Clin. Endocrinol. Metab. 88(8), 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Lindsay RS, Wake DJ, Nair S et al. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase Type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88(6), 2738–2744 (2003).
   PubMed Web of Science ®Google Scholar
• Westerbacka J, Yki-Jarvinen H, Vehkavaara S et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J. Clin. Endocrinol. Metab. 88(10), 4924–4931 (2003).
   PubMed Web of Science ®Google Scholar
• Kannisto K, Pietilainen KH, Ehrenborg E et al. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 89(9), 4414–4421 (2004).
   PubMed Web of Science ®Google Scholar
• Hermanowski-Vosatka A, Mundt SS, Lee M et al. Adipose 11βHSD1 activity increases with obesity and fat cell hypertrophy, In: On Control of Adipogenesis and Obesity. Keystone Symposia, Alberta, CA, USA (2004).
   Google Scholar
• Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase Type 1 in adipose tissue from obese patients: an in situ hybridization study. J. Clin. Endocrinol. Metab. 87(6), 2701–2705 (2002).
   PubMed Web of Science ®Google Scholar
• Mundt SS, Wang Y, Sullivan S et al. In: Depot Difference in Glucocorticoid Metabolism in Human Omental and Subcutaneous Adipose Tissue of Obese Subjects, ENDO 2003. The Endocrinology Society, PA, USA (2003).
   Google Scholar
• Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone->cortisol conversion in subjects with central adiposity. J. Clin. Endocrinol. Metab. 84(3), 1022–1027 (1999).
   PubMed Web of Science ®Google Scholar
• Sandeep TC, Andrew R, Homer NZ et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase Type 1 inhibitor carbenoxolone. Diabetes 54(3), 872–879 (2005).
   PubMed Web of Science ®Google Scholar
• Valsamakis G, Anwar A, Tomlinson JW et al. 11β-hydroxysteroid dehydrogenase Type 1 activity in lean and obese males with Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89(9), 4755–4761 (2004).
   PubMed Web of Science ®Google Scholar
• Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51(4), 1066–1075 (2002).
   PubMed Web of Science ®Google Scholar
• Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker BR. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 54(5), 1364–1370 (2005).
   PubMedGoogle Scholar
• Basu R, Singh RJ, Basu A et al. Obesity and Type 2 diabetes do not alter splanchnic cortisol production in humans. J. Clin. Endocrinol. Metab. 90(7), 3919–3926 (2005).
   PubMed Web of Science ®Google Scholar
• Aldhahi W, Mun E, Goldfine AB. Portal and peripheral cortisol levels in obese humans. Diabetologia 47(5), 833–836 (2004).
   PubMedGoogle Scholar
• Livingstone DE, Walker BR. Is 11β-hydroxysteroid dehydrogenase Type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Pharmacol. Exp. Ther. 305(1), 167–172 (2003).
   PubMed Web of Science ®Google Scholar
• Livingstone DE, Jones GC, Smith K et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141(2), 560–563 (2000).
   PubMed Web of Science ®Google Scholar
• Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11β-hydroxysteroid dehydrogenase Type 1 in obese Zucker rats. J. Endocrinol. 167(3), 533–539 (2000).
   PubMedGoogle Scholar
• Morton NM, Ramage L, Seckl JR. Downregulation of adipose 11β-hydroxysteroid dehydrogenase Type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145(6), 2707–2712 (2004).
   PubMed Web of Science ®Google Scholar
• Hermanowski-Vosatka A, Gerhold D, Mundt SS et al. PPARα agonists reduce 11β-hydroxysteroid dehydrogenase Type 1 in the liver. Biochem. Biophys. Res. Commun. 279(2), 330–336 (2000).
   PubMed Web of Science ®Google Scholar
• Berger J, Tanen M, Elbrecht A et al. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β -hydroxysteroid dehydrogenase Type 1 expression and activity. J. Biol. Chem. 276(16), 12629–12635 (2001).
   PubMedGoogle Scholar
• Duplomb L, Lee Y, Wang MY et al. Increased expression and activity of 11β-HSD-1 in diabetic islets and prevention with troglitazone. Biochem. Biophys. Res. Commun. 313(3), 594–599 (2004).
   PubMedGoogle Scholar
• Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, Gustafsson JA. Liver X receptors downregulate 11β-hydroxysteroid dehydrogenase Type 1 expression and activity. Diabetes 51(8), 2426–2433 (2002).
   PubMed Web of Science ®Google Scholar
• Cai TQ, Wong B, Mundt SS et al. Induction of 11β-hydroxysteroid dehydrogenase Type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J. Steroid Biochem. Mol. Biol. 77(2–3), 117–122 (2001).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Moore J, Cooper MS et al. Regulation of expression of 11β-hydroxysteroid dehydrogenase Type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142(5), 1982–1989 (2001).
   PubMed Web of Science ®Google Scholar
• Hult M, Jornvall H, Oppermann UC. Selective inhibition of human Type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett. 441(1), 25–28 (1998).
   PubMed Web of Science ®Google Scholar
• Ogawa A, Johnson JH, Ohneda M et al. Roles of insulin resistance and β-cell dysfunction in dexamethasone-induced diabetes. J. Clin. Invest. 90(2), 497–504 (1992).
   PubMedGoogle Scholar
• Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 80(11), 3155–3159 (1995).
   PubMed Web of Science ®Google Scholar
• Andrews RC, Rooyackers O, Walker BR. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with Type 2 diabetes. J. Clin. Endocrinol. Metab. 88(1), 285–291 (2003).
   PubMed Web of Science ®Google Scholar
• Fotsch C, Askew BC, Chen JJ. 11β-hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases. Expert Opin. Ther. Patents 15(3), 289–3003 (2005).
   Web of Science ®Google Scholar
• Barf T, Vallgarda J, Emond R et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase Type 1. J Med. Chem. 45(18), 3813–3815 (2002).
   PubMed Web of Science ®Google Scholar
• •Selective nonsteroidal 11β-HSD1 inhibitors with efficacy in murine models of diabetes.
   Google Scholar
• Alberts P, Engblom L, Edling N et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase Type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45(11), 1528–1532 (2002).
   PubMed Web of Science ®Google Scholar
• Alberts P, Nilsson C, Selen G et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase Type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144(11), 4755–4762 (2003).
   PubMed Web of Science ®Google Scholar
• Olson S, Balkovec J, Gao Y-D et al. Selective inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 Adamantyl triazoles as pharmacological agents for the treatment of metabolic syndrome. In: Molecular Controls of Adipogenesis and Obesity. Keystone Symposia, Alberta, Canada, 329 (2004).
   Google Scholar
• Hermanowski-Vosatka A, Balkovec JM, Cheng K et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202(4), 517–527 (2005).
   PubMed Web of Science ®Google Scholar
• Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71(2), 343–353 (1992).
   PubMed Web of Science ®Google Scholar
• Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258(5081), 468–471 (1992).
   PubMed Web of Science ®Google Scholar
• Brem AS, Bina RB, King TC, Morris DJ. Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 31(1 Pt. 2), 459–462 (1998).
   PubMed Web of Science ®Google Scholar
• Thieringer R, Le Grand CB, Carbin L et al. 11β-hydroxysteroid dehydrogenase Type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 167(1), 30–35 (2001).
   PubMed Web of Science ®Google Scholar
• Kumari M, Grahame-Clarke C, Shanks N et al. Chronic stress accelerates atherosclerosis in the apolipoprotein E deficient mouse. Stress, 6(4), 297–299 (2003).
   Google Scholar
• Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21(1), 55–89 (2000).
   PubMed Web of Science ®Google Scholar
• Yeager MP, Guyre PM, Munck AU. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol. Scand. 48(7), 799–813 (2004).
   PubMed Web of Science ®Google Scholar
• Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc. Natl Acad. Sci. USA (PNAS) 96(3), 1059–1064 (1999).
   PubMed Web of Science ®Google Scholar
• Galon J, Franchimont D, Hiroi N et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16(1), 61–71 (2002).
   PubMed Web of Science ®Google Scholar
• Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol. Metab. Clin. North Am. 31(1), 15–36 (2002).
   PubMed Web of Science ®Google Scholar
• McEwen BS. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 22, 105–122 (1999).
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Rothschild AJ, Cassidy F et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry 52(5), 386–392 (2002).
   PubMed Web of Science ®Google Scholar
• Moisan MP, Seckl JR, Edwards CR. 11β-hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 127(3), 1450–1455 (1990).
   PubMed Web of Science ®Google Scholar
• Lakshmi V, Sakai RR, McEwen BS, Monder C. Regional distribution of 11β-hydroxysteroid dehydrogenase in rat brain. Endocrinology 128(4), 1741–1748 (1991).
   PubMed Web of Science ®Google Scholar
• Landfield PW, Waymire JC, Lynch G. Hippocampal aging and adrenocorticoids: quantitative correlations. Science 202(4372), 1098–1102 (1978).
   PubMed Web of Science ®Google Scholar
• Meaney MJ, Aitken DH, van Berkel C, Bhatnagar S, Sapolsky RM. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science 239(4841 Pt. 1), 766–768 (1988).
   PubMed Web of Science ®Google Scholar
• Yau JL, Noble J, Kenyon CJ et al. Lack of tissue glucocorticoid reactivation in 11β -hydroxysteroid dehydrogenase Type 1 knockout mice ameliorates age-related learning impairments. Proc. Natl Acad. Sci. USA 98(8), 4716–4721 (2001).
   PubMedGoogle Scholar
• •11β-HSD1 deficiency in mice improves cognitive functions in aged mice.
   Google Scholar
• Sandeep TC, Yau JL, MacLullich AM et al. 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and Type 2 diabetics. Proc. Natl Acad. Sci. USA 101(17), 6734–6739 (2004).
   PubMed Web of Science ®Google Scholar
• de Quervain DJ, Poirier R, Wollmer MA et al. Glucocorticoid-related genetic susceptibility for Alzheimer’s disease. Hum. Mol. Genet. 13(1), 47–52 (2004).
   PubMedGoogle Scholar
• Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J. Intern. Med. 254(1), 32–44 (2003).
   PubMed Web of Science ®Google Scholar
• Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81(10), 3441–3447 (1996).
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15(6), 993–1000 (2000).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Walker EA, Bland R et al. Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 27(3), 375–381 (2000).
   PubMed Web of Science ®Google Scholar
• Bland R, Worker CA, Noble BS et al. Characterization of 11β-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J. Endocrinol. 161(3), 455–464 (1999).
   PubMedGoogle Scholar
• Cooper MS, Rabbitt EH, Goddard PE et al. Osteoblastic 11β-hydroxysteroid dehydrogenase Type 1 activity increases with age and glucocorticoid exposure. J. Bone Miner. Res. 17(6), 979–986 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Blumsohn A, Goddard PE et al. 11β-hydroxysteroid dehydrogenase Type 1 activity predicts the effects of glucocorticoids on bone. J. Clin. Endocrinol. Metab. 88(8), 3874–3877 (2003).
   PubMed Web of Science ®Google Scholar
• David R, Zangwill L, Briscoe D et al. Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br. J. Ophthalmol. 76(5), 280–283 (1992).
   PubMed Web of Science ®Google Scholar
• Armaly MF. Dexamethasone ocular hypertension and eosinopenia, and glucose tolerance test. Arch. Ophthalmol. 78(2), 193–197 (1967).
   PubMedGoogle Scholar
• Starka L, Obenberger J. Steroids and intraocular pressure. J. Steroid Biochem. Mol. Biol. 7(11–12), 979–983 (1976).
   Google Scholar
• Stokes J, Noble J, Brett L et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11β-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest. Ophthalmol. Vis. Sci. 41(7), 1629–1638 (2000).
   PubMed Web of Science ®Google Scholar
• Rauz S, Walker EA, Shackleton CH et al. Expression and putative role of 11β-hydroxysteroid dehydrogenase isozymes within the human eye. Invest. Ophthalmol. Vis. Sci. 42(9), 2037–2042 (2001).
   PubMed Web of Science ®Google Scholar
• Rauz S, Cheung CM, Wood PJ et al. Inhibition of 11β-hydroxysteroid dehydrogenase Type 1 lowers intraocular pressure in patients with ocular hypertension. QJM 96(7), 481–490 (2003).
   PubMed Web of Science ®Google Scholar
  International Diabetes Foundation metabolic syndrome definition http://wwwidf.org/weedata/docs/metabolic_syndrome_defenition.pdf (Accessed August 2005)
   Google Scholar